Breast cancer: an up‐to‐date review and future perspectives
R Hong, B Xu - Cancer communications, 2022 - Wiley Online Library
Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …
associated with many risk factors, including genetic and hereditary predisposition. Breast …
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
DNA repair pathway choices in CRISPR-Cas9-mediated genome editing
Many clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-
associated protein 9 (Cas9)-based genome editing technologies take advantage of Cas …
associated protein 9 (Cas9)-based genome editing technologies take advantage of Cas …
[HTML][HTML] Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
Y Feng, M Spezia, S Huang, C Yuan, Z Zeng, L Zhang… - Genes & diseases, 2018 - Elsevier
As the most commonly occurring cancer in women worldwide, breast cancer poses a
formidable public health challenge on a global scale. Breast cancer consists of a group of …
formidable public health challenge on a global scale. Breast cancer consists of a group of …
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
JJ Gruber, A Afghahi, K Timms, A DeWees, W Gross… - Nature Cancer, 2022 - nature.com
Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (g BRCA1/2)-mutant
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
X Yang, G Leslie, A Doroszuk, S Schneider… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE To estimate age-specific relative and absolute cancer risks of breast cancer and
to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers …
to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers …
[HTML][HTML] Patterns of somatic structural variation in human cancer genomes
A key mutational process in cancer is structural variation, in which rearrangements delete,
amplify or reorder genomic segments that range in size from kilobases to whole …
amplify or reorder genomic segments that range in size from kilobases to whole …
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
M Tarsounas, P Sung - Nature Reviews Molecular Cell Biology, 2020 - nature.com
The tumour suppressor breast cancer type 1 susceptibility protein (BRCA1) promotes DNA
double-strand break (DSB) repair by homologous recombination and protects DNA …
double-strand break (DSB) repair by homologous recombination and protects DNA …
Fanconi anaemia and cancer: an intricate relationship
G Nalepa, DW Clapp - Nature Reviews Cancer, 2018 - nature.com
Fanconi anaemia (FA) is a genetic disorder that is characterized by bone marrow failure
(BMF), developmental abnormalities and predisposition to cancer. Together with other …
(BMF), developmental abnormalities and predisposition to cancer. Together with other …
Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource
With advances in genomic sequencing technology, the number of reported gene-disease
relationships has rapidly expanded. However, the evidence supporting these claims varies …
relationships has rapidly expanded. However, the evidence supporting these claims varies …